Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

MedinCell Temettü

Temettü kriter kontrolleri 0/6

MedinCell şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	3.5%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-€0.86
Temettü verim tahmini	0%

Son temettü güncellemeleri

Güncelleme yok

Recent updates

MedinCell S.A. (EPA:MEDCL) Analysts Are More Bearish Than They Used To Be

Jul 05

Revenues Tell The Story For MedinCell S.A. (EPA:MEDCL) As Its Stock Soars 30%

Apr 26

Market Participants Recognise MedinCell S.A.'s (EPA:MEDCL) Revenues Pushing Shares 26% Higher

Jan 09

The MedinCell (EPA:MEDCL) Share Price Is Up 75% And Shareholders Are Holding On

Mar 02

Is MedinCell S.A. (EPA:MEDCL) Popular Amongst Insiders?

Jan 08

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: MEDCL şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: MEDCL şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

MedinCell Piyasaya Karşı Temettü Getirisi

MEDCL temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (MEDCL)	n/a
Pazarın Alt %25'i (FR)	2.0%
Pazarın En İyi %25'i (FR)	5.6%
Sektör Ortalaması (Pharmaceuticals)	3.5%
Analist tahmini (MEDCL) (3 yıla kadar)	0%

Önemli Temettü: MEDCL şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, MEDCL şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: MEDCL şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: MEDCL herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

MedinCell Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

MedinCell S.A. Confirms Stéphane Postic as CFO

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

MedinCell S.A. (EPA:MEDCL) Analysts Are More Bearish Than They Used To Be

Consensus revenue estimates fall by 22%

Price target increased by 8.6% to €20.03

New major risk - Financial position

Full year 2024 earnings released

Consensus revenue estimates fall by 14%

Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial

Teva Pharmaceuticals and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia

Revenues Tell The Story For MedinCell S.A. (EPA:MEDCL) As Its Stock Soars 30%

New minor risk - Share price stability

Medincell S.A. Reaches Commercial Stage with the Market Launch by Teva of Uzedy™ for the Treatment of Schizophrenia

Medincell S.A. Appoints Philippe Guy as Chairman of Supervisory Board

MedinCell Announces Chairman Changes

MedinCell S.A., Annual General Meeting, Sep 12, 2024

Teva Pharmaceutical Industries Ltd. Announces Recruitment Completion of Phase 3 Clinical Study of mdc-TJK / Olanzapine Long-Acting Injectable

Market Participants Recognise MedinCell S.A.'s (EPA:MEDCL) Revenues Pushing Shares 26% Higher

Consensus revenue estimates increase by 13%

First half 2024 earnings released

Medincell Announces Successful Completion of Patient Enrollment in the Phase 3 Study of F14 (Mdc-Cwm), A First-In-Class Therapy for Localized Pain Relief After Total Knee Replacement

New minor risk - Shareholder dilution

Consensus revenue estimates fall by 42%

Full year 2023 earnings released

Price target increased by 9.8% to €16.10

Forecast breakeven date pushed back to 2025

Consensus revenue estimates fall by 42%

Medincell Announces Positive Results for the Saive Clinical Study in Prevention of Covid-19 Infection in A Contact-Based Population

MedinCell S.A., Annual General Meeting, Sep 12, 2023

MedinCell S.A. to Report First Half, 2024 Results on Dec 06, 2023

First half 2023 earnings released: €0.55 loss per share (vs €0.47 loss in 1H 2022)

Price target decreased to €14.50

MedinCell Announces the Initiation of Phase 3 Study of F14 (mdc-CWM), A Therapeutic First-In-Class That Aims to Provide Weeks of Localized Pain Relief After Total Knee Replacement

Price target decreased to €14.50

Full year 2022 earnings: Revenues miss analyst expectations

MedinCell Appoints Richard Malamut, MD as Chief Medical Officer

Teva and MedinCell Receive Complete Response Letter for TV-46000/mdc-IRM

MedinCell S.A. Announces Inclusion of First Participants in New Covid-19 Prophylaxis Clinical Trial SAIVE

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

MedinCell Provides an Update on Its Product Portfolio, Following the FDA Acceptance of New Drug Application for the Product mdc-IRM

Teva Pharmaceuticals and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as Treatment for Patients with Schizophrenia

Full year 2021 earnings released

Medincell Collaborates for More Than 10 Years with Ird, Irss and Cirdes to Conduct in Vivo Studies in Burkina Faso About Tackling Residual Transmission of Malaria

The MedinCell (EPA:MEDCL) Share Price Is Up 75% And Shareholders Are Holding On

MedinCell Announces Three New Products Entering Regulatory Development

MedinCell S.A., Annual General Meeting, Sep 10, 2021

New 90-day high: €16.15

Analysts lower revenue estimates to €11.4m

Teva Pharmaceuticals Industries Ltd. and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia

Is MedinCell S.A. (EPA:MEDCL) Popular Amongst Insiders?

New 90-day high: €15.00

First half 2021 earnings released: €0.51 loss per share

New 90-day high: €9.50

New 90-day high: €8.12

MedinCell Initiates the First Clinical Trial of its Covid-19 Prevention Program

New 90-day low - €7.04

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin